



ADD\_SPD602 150 compl 0.5 RR 50 sites







ADD\_SPD602 HA reference 0.5RR 288 enrolled







ADD\_SPD602 Japan 2/3 3 doses to 2 with 225 subjects







ADD\_SPD602-204 8 month site set up







ADD\_SPD602-2xd MDS phII study







ADD\_SPD602-3xab 17Jan2013







ADD\_SPD602-3xc 1070 enrolled







ADD\_SPD602-3xc 674 enrolled 23Jan2013





ADD\_SPD602-3xf apr start





ADD\_Tecfidera Switch 164 Pts/40 Sites

